Hims & Hers Health Registered (A) WKN: A2QMYY ISIN: US4330001060 Forum: Aktien Thema: Hauptdiskussion

03.03.

Wann erscheinen die Q4 Zahlen? Verschiedene Daten hier gelesen

Angelstar, das klingt so wild, dass ich dir das abnehme 😄

Angelstar, das klingt so wild, dass ich dir das abnehme 😄

In words that are sure to please executives at Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY), President Trump's nominee for HHS Secretary, Robert F. Kennedy Jr., called GLP-1 medications used for weight loss "miracle drugs." Kennedy Jr. made the comments Thursday during a confirmation hearing before the Senate Health, Education, Labor and Pension Committee. Novo and Lilly make the two most popular GLP-1 weight loss treatments, Wegovy (semaglutide) and Zepbound (tirzepatide). The comments are notable as the nominee has previously made comments critical of using drugs to tackle obesity, preferring diet and lifestyle changes instead. In December, Kennedy Jr. appeared to be softening his stance when during a brief interview with CNBC on the floor of the NYSE he said that "the first line of response should be lifestyle, it should be eating well, making sure that you don't get obese, and that those GLP drugs have a place."

Hier endet die Reise noch nicht mein alter Freund